US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock
(NY:
ATNM
)
1.130
+0.070 (+6.60%)
Official Closing Price
Updated: 4:10 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Actinium Pharmaceuticals, Inc. (Delaware) Common Stock
< Previous
1
2
3
4
5
Next >
Why Is Actinium Pharmaceuticals Stock Rising Today?
↗
December 12, 2025
The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models.
Via
Stocktwits
Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia
December 11, 2025
Via
AB Newswire
Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins European Phase 1 Trial of Nectin-4 Targeted Alpha Therapy for Multiple Solid Tumors
December 10, 2025
Via
AB Newswire
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer
December 09, 2025
Via
AB Newswire
ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa
December 08, 2025
Via
AB Newswire
Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa
December 08, 2025
Via
AB Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
May 27, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
May 23, 2025
From
Rosen Law Firm
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Ultra Clean, and SoundHound and Encourages Investors to Contact the Firm
May 21, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and SoundHound and Encourages Investors to Contact the Firm
May 14, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
May 14, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
May 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - ATNM
May 11, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
May 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
May 08, 2025
From
Kirby McInerney LLP
Via
Business Wire
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
April 29, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
April 29, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
April 28, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 26, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM
April 25, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 23, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
April 21, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 20, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
April 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
April 16, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
April 15, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
April 13, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 09, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Shareholder Alert: Scott+Scott Attorneys at Law LLP Issues Corrected Notice to Clarify Deadline To Seek Appointment As Lead Plaintiff In Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
April 08, 2025
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
April 07, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
